Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001232982 | SCV001405558 | likely benign | Duchenne muscular dystrophy | 2024-10-19 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001534502 | SCV001751437 | likely benign | not provided | 2020-12-08 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002375240 | SCV002688350 | uncertain significance | Cardiovascular phenotype | 2023-09-08 | criteria provided, single submitter | clinical testing | The p.R3160C variant (also known as c.9478C>T), located in coding exon 65 of the DMD gene, results from a C to T substitution at nucleotide position 9478. The arginine at codon 3160 is replaced by cysteine, an amino acid with highly dissimilar properties. Based on data from gnomAD, the T allele has an overall frequency of 0.001% (2/183399) total alleles studied, including a total of 2 hemizygotes. The highest observed frequency was 0.002% (2/81868) of European non-Finnish alleles. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV001534502 | SCV003829525 | uncertain significance | not provided | 2019-08-27 | criteria provided, single submitter | clinical testing |